【大失敗】マンジャロでリバウンド者が続出する理由を暴露します

👉️ Manjaro's online consultations are available via [Official LINE] https://lstep.app/zXFPzsp ◆━━━━━━━━━━━━━━━━━━◆ \ Achieve your last diet ever! 🔥 / ✅ Say goodbye to strict exercise and diet restrictions! ✅ Over 10,000 successful cases! Knowledge and clinical experience based on medical evidence ✅ Thorough follow-up after prescription \ For consultations and online consultations, please use our official LINE 💁‍♂️ / Dr. Kenshin will respond directly! https://lstep.app/zXFPzsp [Watch this video about the relationship between sleep and dieting] [Shocking] Sleep deprivation is a direct path to obesity! I'll tell you about a weight-loss drug that surpasses Manjaro    • 【衝撃】睡眠不足はデブまっしぐら！マンジャロ超えの痩せ薬を教えます   ▼Video Table of Contents▼ 00:00 About this video 01:23 About Manjaro 04:10 Rebound prevention #1 08:55 Rebound prevention #2 13:12 Rebound prevention #3 14:14 How to avoid rebounding ●Official LINE https://lstep.app/zXFPzsp ●Instagram   / tsukuba_ken_clinic   ●TikTok   / diet_dr.kenshin   ●Homepage https://tsukuken.clinic ●For interviews/work inquiries, please contact us here [email protected] 🔹We are looking for colleagues to work with us | Doctor/Staff recruitment Tsukuba Ken Clinic is committed to new forms of medical care, including online private consultations, online insured consultations, general outpatient care, and preventive medicine. We value flexible responses and teamwork to deliver the necessary medical care to each individual patient, rather than a one-size-fits-all approach. We are looking for colleagues who want to grow together and create better medical care. 📍【Recruitment Information & Entry Here】 ▶︎ https://tsukuken.clinic/recruit/ *Please check the link above for details on specific job titles, duties, and working styles. ────────────────── 【About Treatment】(Disclosure of Important Matters) 1. About Medical Treatment and Prescriptions at Our Clinic At our clinic, we may prescribe type 2 diabetes medications (GLP-1 receptor agonists, SGLT2 inhibitors, metformin, etc.) as private consultations (for the purpose of obesity treatment) at the discretion of the physician. Since the use of these medications for the purpose of obesity treatment is not approved in Japan, this constitutes off-label use. We make a comprehensive judgment based on examination, test results, and medical history, and we cannot prescribe these medications to all patients. 2. Main Purpose and Indications of Treatment All medications are approved for the purpose of controlling blood glucose in type 2 diabetes. Use for obesity treatment will be carried out only after thorough explanation and informed consent, taking into account domestic and international approval status and academic society guidelines. 3. Individual Differences in Efficacy, Side Effects, and Risks Taking the medication or injecting it does not necessarily guarantee a certain level of weight loss. There are significant individual differences in effectiveness, and it is essential to use it in conjunction with lifestyle changes, dietary therapy, and exercise therapy. Side effects such as hypoglycemia and gastrointestinal symptoms may occur; consult a doctor immediately if you experience any discomfort. 4. Possibility of Tests and Additional Treatment Regular tests (blood, urine, etc.) may be necessary to continue treatment. Consultation fees, test fees, and additional medication costs may be incurred separately. 5. Precautions Regarding Private Medical Treatment Prescriptions for obesity treatment are not covered by health insurance (full self-payment). Because it is an off-label use, it may not be covered by the national drug side effect relief system. 6. Comparison with Other Treatments and Guarantees This treatment is merely one option and does not guarantee superiority over other medical institutions or other treatments. Treatment effectiveness and the risk of side effects vary from person to person, and the expected results are not always guaranteed. ────────────────── ●GLP-1 Receptor Agonist (Oral Medication: Rybelsus) 【Treatment Details】 Rybelsus is an oral GLP-1 receptor agonist used to control blood glucose in type 2 diabetes. At our hospital, it may be prescribed for obesity treatment at the doctor's discretion (off-label use). Weight loss is expected due to its appetite-suppressing effect and sustained satiety. 【Dosage and Administration】 Take once daily before breakfast with 120 mL or less of water. Avoid eating or drinking for 30 minutes after taking the medication (to maximize its effect). The initial dose is 3 mg, increased to 7 mg after one month, and can be increased up to 14 mg as needed. [Standard Costs] Rybelsus 3mg 30-day supply: ¥8,480 7mg 30-day supply: ¥18,480 14mg 30-day supply: ¥26,980 [Main Risks and Side Effects] Gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), loss of appetite, acute pancreatitis (extremely rare) [Regarding the Use of Unapproved Drugs, etc...